Susquehanna International Group
VERV

Susquehanna International Group’s Verve Therapeutics VERV Stock Holding History

Susquehanna International Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-170,200
Closed -$1.91M – 13991
2025
Q2 		$1.91M Buy
170,200
+97,600
+134% +$556K ﹤0.01% 5881
2025
Q1 		$332K Buy
72,600
+20,300
+39% +$136K ﹤0.01% 9852
2024
Q4 		$295K Buy
52,300
+38,700
+285% +$218K ﹤0.01% 9868
2024
Q3 		$65.8K Buy
+13,600
New +$79K ﹤0.01% 11268
2024
Q2 		– Sell
-84,700
Closed -$1.12M – 13304
2024
Q1 		$1.12M Sell
84,700
-31,400
-27% -$416K ﹤0.01% 6606
2023
Q4 		$1.62M Buy
116,100
+11,700
+11% +$145K ﹤0.01% 5823
2023
Q3 		$1.38M Buy
104,400
+90,700
+662% +$1.46M ﹤0.01% 5911
2023
Q2 		$257K Sell
13,700
-26,200
-66% -$436K ﹤0.01% 9756
2023
Q1 		$575K Sell
39,900
-153,500
-79% -$3.01M ﹤0.01% 8225
2022
Q4 		$3.74M Buy
193,400
+47,700
+33% +$1.26M ﹤0.01% 3673
2022
Q3 		$5M Buy
145,700
+34,200
+31% +$1.09M ﹤0.01% 3145
2022
Q2 		$1.7M Buy
+111,500
New +$1.73M ﹤0.01% 5251

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Susquehanna International Group's VERV Position: Q3 2025 in Review

Susquehanna International Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 82,365 shares — an estimated $925K sold.

Susquehanna International Group first reported a position in VERV in Q2 2021 and held it in 16 quarters. The position peaked at $3.35M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Susquehanna International Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 82,365 Verve Therapeutics shares in Q3 2025, an estimated $925K.
  • Susquehanna International Group first reported a position in Verve Therapeutics in Q2 2021 and held it in 16 quarters.
  • Susquehanna International Group's Verve Therapeutics position peaked at $3.35M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.